Mitsubishi UFJ Trust & Banking Corp boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 658,355 shares of the pharmaceutical company’s stock after buying an additional 635 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.26% of Vertex Pharmaceuticals worth $84,842,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of VRTX. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in shares of Vertex Pharmaceuticals by 13.5% in the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 57,250 shares of the pharmaceutical company’s stock valued at $7,378,000 after buying an additional 6,788 shares during the last quarter. Airain ltd purchased a new position in shares of Vertex Pharmaceuticals during the second quarter valued at $4,620,000. Andra AP fonden purchased a new position in shares of Vertex Pharmaceuticals during the second quarter valued at $1,237,000. Robeco Institutional Asset Management B.V. raised its position in shares of Vertex Pharmaceuticals by 1,526.7% in the second quarter. Robeco Institutional Asset Management B.V. now owns 15,633 shares of the pharmaceutical company’s stock valued at $2,013,000 after buying an additional 14,672 shares during the last quarter. Finally, Penserra Capital Management LLC purchased a new position in shares of Vertex Pharmaceuticals during the second quarter valued at $1,334,000. 94.89% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 153.27 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $167.86. The company has a market cap of $38.64 billion, a P/E ratio of 147.23 and a beta of 1.77. The company’s 50 day moving average price is $149.67 and its 200 day moving average price is $120.19.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The business had revenue of $544.10 million during the quarter, compared to analyst estimates of $489.95 million. During the same period in the previous year, the business earned $0.24 EPS. Vertex Pharmaceuticals’s revenue was up 26.1% compared to the same quarter last year. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.60 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2017/08/27/mitsubishi-ufj-trust-banking-corp-boosts-stake-in-vertex-pharmaceuticals-incorporated-vrtx.html.

VRTX has been the topic of a number of analyst reports. Jefferies Group LLC reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 22nd. BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 19th. Zacks Investment Research lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Cowen and Company reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. Finally, Argus increased their price objective on Vertex Pharmaceuticals from $71.46 to $175.00 and gave the company a “buy” rating in a report on Tuesday, August 1st. Six equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. Vertex Pharmaceuticals presently has an average rating of “Buy” and an average target price of $162.88.

In other news, SVP Paul M. Silva sold 43,443 shares of the business’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $161.07, for a total transaction of $6,997,364.01. Following the completion of the transaction, the senior vice president now directly owns 26,516 shares in the company, valued at approximately $4,270,932.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Paul M. Silva sold 2,577 shares of the business’s stock in a transaction on Wednesday, June 21st. The shares were sold at an average price of $133.36, for a total transaction of $343,668.72. Following the transaction, the senior vice president now owns 22,648 shares of the company’s stock, valued at $3,020,337.28. The disclosure for this sale can be found here. Insiders sold a total of 751,042 shares of company stock valued at $113,078,257 over the last quarter. 1.80% of the stock is owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.